glp 1 agonist uses Frontiers Benefits and drawbacks of GLP-1

Hormone therapy is a tool

This expansion by the two largest obesity players into CR drugs suggests both companies are actively diversifying beyond GLP-1R drugs to secure early positions in emerging segments of obesity.

H., & Dailey, M

Lifestyle variables are still active

Additional well-designed, prospective studies are needed to confirm the potential benefit of GLP-1 receptor agonist treatment for patients with advanced CKD or ESKD." For further information: DOI: 10.1001/jamanetworkopen.2022.1169 Keywords: CKD, ESKD, GLP-1 receptor agonist, DPP-4 inhibitors, type 2 diabetes, JAMA Network Open, chronic kidney disease, end-stage kidney disease, National Health Insurance Research Database of Taiwan, MACCE, Mortality rate

Irisin and Incretin Hormones: Similarities, Differences, and Implications in Type 2 Diabetes and Obesity